This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Immunoglobulin kappa constant.
In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268).
Human | |
---|---|
Gene Name: | IGKC |
Uniprot: | P01834 |
Entrez: | 3514 |
Belongs to: |
---|
No superfamily |
HCAK1; IGKCD; immunoglobulin kappa constant; Km; MGC111575; MGC62011; MGC72072; MGC88770; MGC88771; MGC88809
Mass (kDA):
11.765 kDA
Human | |
---|---|
Location: | 2p11.2 |
Sequence: | 2; NC_000002.12 (88857361..88857683, complement) |
Secreted. Cell membrane.
This article will cover Steven Boster's research and the Immunoglobulin k c chain (IGKC). It will also discuss the role of IGKC for cancer. Continue reading for more information about Boster, IGKC, as well as the chemotherapy responses. This article will help to decide if IGKC test is right in your case. Let's first look at what IGKC is, and how it can be useful in cancer treatment.
In Zimbabwe, routine immunization has been hard hit by the COVID-19 Pandemic. However, local health workers are working to protect children against this deadly disease. Unfortunately, most COVID-19 antibodies tests do not detect vaccine-derived antibodies and do not provide enough protection. If a child in Makoko can access routine immunisation, their lives can change dramatically. And, if an artificial intelligence can be used to help overcome vaccine hesitancy, this could be a huge breakthrough for a child's health.
A novel signature of cancer cells, called the TGFb-EMT signature, has been developed. The signature consists of 138 genes that are expressed predominantly in tumor cells and reflects the status of the cancer at a given time. The signature is colored according its frequency. Samples that have a high score are more likely to die. The TGFb-EMT signature for the high-risk cohort is higher than that of those with a lower score.
The signature not only predicts overall survival but also predicts metastasis-free survival among patients with NSCLC. The tumor cells in a patient with this type of cancer must detach from neighboring cells and invade adjacent tissues. Similarly, a successful metastasis requires the tumor cells to survive in the blood and enter distant organs. The tumor cells should also be able stay alive in the bloodstream after they have been trapped on the vessel walls.
This study shows that a fusion gene, IGKC, is a good predictor of response to chemotherapy. It was independent of HER2 level, progesterone receptor status, and type or chemotherapy. Multivariate and univariate Cox regression analyses found strong associations between IGKC levels and overall survival. The study also indicated that IGKC gene expression may be a good predictor for chemosensitivity in patients suffering from ER-negative cancer.
Using IGKC as a biomarker in cancer patients can predict the response to neoadjuvant medication. It is a good biomarker because it can be tested on FFPE tissue samples. It supports the idea that immunotherapy may be possible. Its protective effects on the immune system suggest that chemotherapy may help to treat the cancer. There are also many other benefits of using this marker. It is easy to use. It can also serve as a routine diagnostic tool.
The IGKC genes are representative B-cell metagenes. Each spot is one of 60 genes. The color red indicates that the gene IGKC has been identified. IGKC has a high average Pearson correlation, which is a measure the gene's ability discriminate between patients. The better the prognosis, the higher the AUC. This gene can be used as a predictor of response to chemotherapy.
IGKC expression is a robust immune marker. IGKC expression predicts metastasis free survival and chemosensitivity. It also facilitates understanding of the role of humoral immune system in cancer development. This study has implications for clinicians and patients with cancer. So, if you are suffering from a cancer and are worried that immunotherapy might not work, IGKC could be an excellent option.
Using immunohistochemistry, researchers were able to identify a tumor's response to chemotherapy. It detected CD20 in 11 tumours. CD20+ tumors had a median number (1500) of B cells. A higher B cell count means a longer life expectancy. One tumour had IGKC gene expression. The study also showed that a high IGKC level could predict relapse.
PMID: 5586923 by Hilschmann N.; The complete amino acid sequence of Bence Jones protein Cum (kappa- type).
PMID: 4893682 by Titani K., et al. The amino acid sequence of a kappa type Bence-Jones protein. 3. The complete sequence and the location of the disulfide bridges.